Analysis of local recurrence causes in uveal melanoma patients treated with
125I brachytherapy
intraocular tumour
local recurrence
local relapse
uveal melanoma
uveal melanoma treatment
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
30
09
2019
accepted:
30
11
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
24
1
2020
Statut:
ppublish
Résumé
To perform a retrospective analysis of factors which might affect the occurrence of a relapse of uveal melanoma after The analysis concerned 343 patients treated in the years 2001-2012. The effect on local recurrence of such factors as patient's sex, age, tumour size, shape, pigmentation, location, presence of orange pigment or petechiae on tumour surface, retinal detachment, and blood or dispersed pigment in vitreous body were studied. Additional analysis concerned physical properties of brachytherapy (total dose, irradiation dose applied to tumour apex and base and irradiation time). Two groups of patients were distinguished: with and without a relapse. The diagnostic criterion for the relapse was growth of the tumour base or height by 0.5 mm. Local recurrence of the uveal melanoma was observed in 29 patients (8.5%). Recurrences occurred with significantly higher frequency ( Treatment of uveal melanomas with
Identifiants
pubmed: 31969914
doi: 10.5114/jcb.2019.90985
pii: 39234
pmc: PMC6964341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
554-562Informations de copyright
Copyright © 2019 Termedia.
Références
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
ISRN Ophthalmol. 2014 Mar 09;2014:950975
pubmed: 24734198
Arch Ophthalmol. 1992 Feb;110(2):245-50
pubmed: 1531290
Brachytherapy. 2015 Sep-Oct;14(5):726-33
pubmed: 26051804
J Contemp Brachytherapy. 2017 Oct;9(5):453-465
pubmed: 29204166
Optom Vis Sci. 2001 Jul;78(7):483-91
pubmed: 11503936
Br J Ophthalmol. 2013 Jul;97(7):804-11
pubmed: 23645818
Ophthalmology. 2016 Jan;123(1):86-91
pubmed: 26505803
J Contemp Brachytherapy. 2019 Feb;11(1):54-60
pubmed: 30911311
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Cancer. 1996 Jun 1;77(11):2356-62
pubmed: 8635107
J Contemp Brachytherapy. 2017 Jun;9(3):287-295
pubmed: 28725254
Ophthalmology. 2002 Dec;109(12):2197-206
pubmed: 12466159
Anticancer Res. 2017 Dec;37(12):6541-6549
pubmed: 29187428
Am J Ophthalmol. 2017 Aug;180:39-45
pubmed: 28572063
Ocul Oncol Pathol. 2017 Sep;3(3):193-198
pubmed: 29071269
Eye (Lond). 2015 Aug;29(8):1027-35
pubmed: 26248525
J Egypt Natl Canc Inst. 2016 Jun;28(2):65-72
pubmed: 26975730
Sci Rep. 2019 Jun 24;9(1):9142
pubmed: 31235702
Klin Oczna. 2005;107(1-3):140-2
pubmed: 16052827
Lab Invest. 2017 Jun;97(6):706-724
pubmed: 28218743
Acta Ophthalmol Scand. 2004 Oct;82(5):509-16
pubmed: 15453845
J Contemp Brachytherapy. 2018 Aug;10(4):337-346
pubmed: 30237817
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):127-36
pubmed: 24613808
J Contemp Brachytherapy. 2018 Dec;10(6):532-541
pubmed: 30662476
Am J Ophthalmol. 2017 May;177:9-16
pubmed: 28163118
Klin Oczna. 2012;114(3):173-9
pubmed: 23373396
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763
Biochem J. 2012 Jan 1;441(1):61-76
pubmed: 22168439
J Contemp Brachytherapy. 2018 Aug;10(4):347-359
pubmed: 30237818